Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-20Clinical Trial Update: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating cadonilimab combined with chemotherapy as first- or second-line treatment for recurrent or metastatic tr…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). [Phase 1]
Phase 1 study evaluating novel immunotherapy combinations in triple negative breast cancer has been terminated; sponsor is Novartis.
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer [Phase 2]
A Phase 2 neoadjuvant trial is evaluating Ivonescimab in combination with chemotherapy for triple-negative breast cancer, and the study is c…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
This completed clinical trial investigated the relationship between stromal tumor-infiltrating lymphocyte (TIL) levels and immune checkpoint…
-
CLINICAL_TRIALS research · 2025-05-16Clinical Trial Update: Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy [Phase 2]
Phase 2 clinical trial evaluating immune PET imaging and proteomics to assess response to spatially fractionated or palliative radiotherapy …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer [Phase 1, Phase 2]
This update describes a Phase 1/Phase 2 clinical trial evaluating seviteronel in combination with chemotherapy for androgen-receptor–positiv…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
A clinical trial evaluating pembrolizumab with neoadjuvant chemo-immunotherapy for early-stage triple-negative breast cancer is currently re…
-
CLINICAL_TRIALS research · 2025-05-09Clinical Trial Update: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC [Phase 3]
Phase 3 clinical trial evaluating Adagloxad Simolenin (OBI-822)/OBI-821 as adjuvant therapy for Globo H positive triple-negative breast canc…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating BL-B01D1 in combination with a PD-1 monoclonal antibody for unresectable locally advanced or recurren…
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer [Phase 1, Phase 2]
Esperas Pharma completed a Phase 1/2 study of LY2880070 in adults with advanced or metastatic cancer, including colorectal cancer.
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC [Phase 2]
A Phase 2 clinical trial is investigating trilaciclib combined with an anti-PD-1 antibody and chemotherapy for locally advanced triple-negat…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients [Phase 2]
Phase 2 trial evaluating neoadjuvant chemotherapy with or without a GnRH agonist in premenopausal patients with triple-negative early breast…
-
CLINICAL_TRIALS research · 2025-04-24Clinical Trial Update: The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors [Phase 1]
Phase 1 trial update studying the immune effects of a fermented wheat germ extract added to standard checkpoint inhibitor therapy in patient…
-
CLINICAL_TRIALS research · 2025-04-23Clinical Trial Update: OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
This entry describes a clinical trial named OPTImaL investigating optimized treatment for patients with early-stage triple-negative breast c…
-
CLINICAL_TRIALS research · 2025-04-23Clinical Trial Update: TNBC Gut Microbiota During Neoadjuvant Treatment [NA]
This clinical trial update describes a study examining gut microbiota changes during neoadjuvant treatment for triple-negative breast cancer…
-
CLINICAL_TRIALS research · 2025-04-22Clinical Trial Update: Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics [Phase 1]
A Phase 1 trial evaluating ribociclib plus belinostat for metastatic triple-negative breast cancer and recurrent ovarian cancer, with genomi…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer [Phase 1, Phase 2]
Window-of-opportunity neoadjuvant trial testing olaparib plus durvalumab in triple-negative or low ER+ breast cancer across Phase 1 and Phas…
-
CLINICAL_TRIALS trial_result · 2025-04-15Clinical Trial Update: Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial update evaluating the combination of veliparib and irinotecan hydrochloride in patients with metastatic or unresectable solid …
-
CLINICAL_TRIALS trial_result · 2025-04-15Clinical Trial Update: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 2, Phase 3]
The clinical trial evaluating B013 in combination with Nab-Paclitaxel for locally advanced or metastatic triple-negative breast cancer has c…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: TH1902 in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for TH1902 in patients with advanced solid tumors. The study is currently active/not recruiting and …
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel [Phase 1]
Phase 1 study evaluating the safety and tolerability of a PARP inhibitor in combination with carboplatin and/or paclitaxel in patients with …
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Viscum Album for TNBC on Adjuvant Pembrolizumab [Phase 4]
Phase 4 clinical trial assessing Viscum Album in combination with adjuvant pembrolizumab for triple-negative breast cancer; currently recrui…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer [Phase 3]
A Phase 3 randomized trial compares neoadjuvant weekly paclitaxel alone to paclitaxel plus weekly carboplatin in women with large operable o…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: PRE-I-SPY Phase I/Ib Oncology Platform Program [Phase 1]
Pre-I-SPY Phase I/Ib oncology platform program update with Phase 1 recruitment ongoing across multiple breast cancer indications, including …
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) [Phase 1]
JEWEL-101 is a Phase 1 trial of XB002 in patients with solid tumors, covering multiple indications. The study has completed.